Myelodysplastic syndromes - azacitidine - NICE TAG TA218

1.1 Azacitidine is recommended as a treatment option for adults who are not eligible for haematopoietic stem cell transplantation and have:

intermediate-2 and high-risk myelodysplastic syndromes according to the International Prognostic Scoring System (IPSS) or
chronic myelomonocytic leukaemia with 10–29% marrow blasts without myeloproliferative disorder or
acute myeloid leukaemia with 20–30% blasts and multilineage dysplasia, according to the World Health Organization classification and
if the manufacturer provides azacitidine with the discount agreed as part of the patient access scheme.